Home Newsfeeds Erste Group Upgrades Merck & Co to Buy

Erste Group Upgrades Merck & Co to Buy

Erste Group analyst Hans Engel upgrades Merck & Co (NYSE:MRK) from Hold to Buy.

byBenzinga Newsdesk

August 25, 2022

1 minute read

Erste Group analyst Hans Engel upgrades Merck & Co (NYSE:MRK) from Hold to Buy.

Analyst Ratings

Expert Ratings for Halozyme Therapeutics

By Benzinga Insights

August 15, 8:00 AM

Analysts have provided the following ratings for Halozyme Therapeutics (NASDAQ:HALO) within the last quarter: Bullish Somewhat Bullish Indifferent…

HALO

Tesla Retail Shareholder Who Poured $3.5B Into EV Stock Screams Foul Over ‘Magician’ Elon Musk’s Pay Package Plan, Urges Other Investors To Vote No: ‘Don’t Be A Sucker’

By Benzinga Neuro

May 5, 11:19 PM

He referred to Musk's supporters as "brainless suckers" and accused Tesla's mission to accelerate the world's transition to sustainable energy as a "ruse to suck in naive investors and engineers."

TSLA

GSK and Spero Therapeutics Announced Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr; Spero to Receive $66M Upfront Plus Potential Milestones Up to $375M

By Charles Gross

September 22, 4:53 AM

GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agreement for Spero's late-stage antibiotic asset, tebipenem HBr.

GSK